# Enzymes of physiological amyloidogenesis control pathological amyloid toxicity

**Authors:** Michael Bokros, Alex Grunfeld, Nathan C Balukoff, Jessica Bouviere, Eléonore Beurel, Stephen Lee

PMC · DOI: 10.26508/lsa.202503493 · 2026-03-18

## TL;DR

This study shows that enzymes involved in RNA processing can control the toxicity of amyloid proteins linked to Alzheimer's and Parkinson's diseases.

## Contribution

The study reveals that RNA tailing and decay enzymes regulate pathological amyloid toxicity in neurodegenerative disease models.

## Key findings

- TENT4b and TENT2 enzymes reduce β-amyloid and α-synuclein toxicity by forming nontoxic amyloid assemblies.
- Exosc10 enhances amyloid toxicity, and its depletion prevents cognitive decline in mouse models.
- Physiological amyloidogenesis pathways influence the progression of pathological amyloid diseases.

## Abstract

This study finds that modulating RNA tailing and decay enzymes can regulate proteotoxicity in Alzheimer’s and Parkinson’s disease models.

Physiological amyloidogenesis drives the formation of functional amyloids involved in various biochemical pathways. We recently showed that the RNA tailing and decay machinery controls the maturation of intracellular amyloid-like aggregates. This raises the question of whether enzymes that participate in the maturation of physiological amyloids are involved in pathological amyloidogenesis implicated in human proteopathies. Using Caenorhabditis elegans and mouse models of pathological amyloids, we show that manipulating the RNA tailing–decay axis alters the toxicity of β-amyloid and α-synuclein involved in Alzheimer’s and Parkinson’s diseases, respectively. The RNA tailing enzymes TENT4b and TENT2 protect against β-amyloid– and α-synuclein–induced toxicity by facilitating the formation of nontoxic amyloidogenic assemblies. In contrast, the RNA exonuclease Exosc10 potentiates pathological amyloid toxicity. Remarkably, Exosc10 depletion prevents cognitive decline and restores memory in two different mouse models of β-amyloid neurotoxicity. Taken together, these results suggest that pathways of physiological amyloidogenesis participate in pathological amyloid etiology.

## Linked entities

- **Genes:** TENT4B (terminal nucleotidyltransferase 4B) [NCBI Gene 64282], TENT2 (terminal nucleotidyltransferase 2) [NCBI Gene 167153], EXOSC10 (exosome component 10) [NCBI Gene 5394]
- **Diseases:** Alzheimer’s disease (MONDO:0004975), Parkinson’s disease (MONDO:0005180)
- **Species:** Caenorhabditis elegans (taxon 6239), Mus musculus (taxon 10090)

## Full-text entities

- **Genes:** Tent4a (terminal nucleotidyltransferase 4A) [NCBI Gene 210106] {aka LAK-1, POLK, Papd7, Pols, TRF4, TRF4-1}, Exosc10 (exosome component 10) [NCBI Gene 50912] {aka PM-Scl, PM/Scl-100, Pmscl2, RRP6, p2, p3}, Snca (synuclein, alpha) [NCBI Gene 20617] {aka NACP, alpha-Syn, alphaSYN}, Actb (actin, beta) [NCBI Gene 11461] {aka Actx, E430023M04Rik, beta-actin}, Anxa11os (annexin A11, opposite strand) [NCBI Gene 105245705] {aka Gm9872}, gld-2 (Poly(A) RNA polymerase gld-2;polynucleotide adenylyltransferase) [NCBI Gene 172338], Tent2 (terminal nucleotidyltransferase 2) [NCBI Gene 100715] {aka 8030446C20Rik, GLD-2, Gld2, Papd4}, gld-4 (Poly(A) RNA polymerase gld-4) [NCBI Gene 172735], Cd55b (CD55 molecule, decay accelerating factor for complement B) [NCBI Gene 13137] {aka Daf, Daf-TM, Daf2, TM-DAF}, crn-3 (Exosome complex component 10 homolog) [NCBI Gene 3565889], TENT4B (terminal nucleotidyltransferase 4B) [NCBI Gene 64282] {aka PAPD5, TRF4-2, TUT3}, daf-2 (Insulin-like receptor subunit beta;Protein kinase domain-containing protein;receptor protein-tyrosine kinase) [NCBI Gene 175410], EXOSC10 (exosome component 10) [NCBI Gene 5394] {aka PM-Scl, PM/Scl-100, PMSCL, PMSCL2, RRP6, Rrp6p}
- **Diseases:** Alzheimer's and Parkinson's diseases (MESH:D010300), cognitive decline (MESH:D003072), toxicity (MESH:D064420), proteopathic disorders (MESH:D009358), Paralysis (MESH:D010243), AD (MESH:D000544), amyloid (MESH:C000718787), amyloid toxicity (MESH:D017772), anxiety (MESH:D001007), memory impairment (MESH:D008569)
- **Chemicals:** 6E10 (-), PVDF (MESH:C024865), EGTA (MESH:D004533), sodium vanadate (MESH:D014638), OCT (MESH:C051883), NP-40 (MESH:C010615), Triton X-100 (MESH:D017830), Alexa 594 (MESH:C417664), ethanol (MESH:D000431), SDS (MESH:D012967), DAPI (MESH:C007293), leupeptin (MESH:C032854), sodium citrate (MESH:D000077559), agar (MESH:D000362), okadaic acid (MESH:D019319), glycerol (MESH:D005990), thioflavin S (MESH:C009462), Hoechst 33258 (MESH:D006690), EDTA (MESH:D004492), NaN3 (MESH:D019810), sodium fluoride (MESH:D012969), pepstatin (MESH:C031375), PBS (MESH:D007854), Tween (MESH:D011136), sucrose (MESH:D013395), NaCl (MESH:D012965), formic acid (MESH:C030544)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Caenorhabditis elegans (species) [taxon 6239], Homo sapiens (human, species) [taxon 9606], C. elegans [taxon 328850]
- **Mutations:** P301L
- **Cell lines:** TENT2GLD-2 — Homo sapiens (Human), Krabbe disease, Induced pluripotent stem cell (CVCL_A5GE), NL5901 — Homo sapiens (Human), Induced pluripotent stem cell (CVCL_1E71), CL2006 — Homo sapiens (Human), 5' 10' methylenetetrahydrofolate reductase deficiency, Finite cell line (CVCL_RA71), HT115 — Homo sapiens (Human), Colon carcinoma, Cancer cell line (CVCL_2520)

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13000121/full.md

---
Source: https://tomesphere.com/paper/PMC13000121